TY - JOUR T1 - Candidate drug replacements for quinacrine in cutaneous lupus erythematosus JF - Lupus Science & Medicine JO - Lupus Sci Med DO - 10.1136/lupus-2020-000430 VL - 7 IS - 1 SP - e000430 AU - Daisy Yan AU - Robert Borucki AU - Richard D Sontheimer AU - Victoria P Werth Y1 - 2020/10/01 UR - http://lupus.bmj.com/content/7/1/e000430.abstract N2 - Cutaneous lupus erythematosus (CLE) is a disfiguring and potentially disabling disease that causes significant morbidity in patients. Antimalarials are an important class of medication used to treat this disease and have been the first-line systemic therapy since the 1950s. Quinacrine, in particular, is used as an adjuvant therapy to other antimalarials for improved control of CLE. Quinacrine is currently unavailable in the USA, which has taken away an important component of the treatment regimen of patients with CLE. This paper reviews the evidence of available local and systemic therapies in order to assist providers in choosing alternative treatments for patients who previously benefited from quinacrine therapy. ER -